Comparative Pharmacology
Head-to-head clinical analysis: ROBAXIN versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXIN versus TRANCOPAL.
ROBAXIN vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant